Our fight with cancer is personal
Adaptimmune (adaptimmune.com) scores 80 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 70th percentile of 11055 Healthcare brands.
Adaptimmune is a clinical-stage biopharmaceutical company headquartered in Abingdon-on-Thames, United Kingdom, founded in 2008. The company develops novel cancer immunotherapy products, engineering cell therapies based on advanced T-cell receptor (TCR) technology to help the body's own immune cells target and fight cancer. Its work is aimed at cancer patients with limited treatment options, and it engages healthcare providers, biopharmaceutical investors, and industry partners in the advancement of cell therapy science.
| Brand Name | Adaptimmune |
|---|---|
| Domain | adaptimmune.com |
| Industry | Healthcare |
| Founded | 2008 |
| Headquarters | Abingdon-on-Thames |
| Main Competitors | Immunocore (75/100), Iovance Biotherapeutics, Autolus Therapeutics, Cabaletta Bio, PACT Pharma, Kite Pharma (Gilead) (83/100), Novartis (71/100), Bristol Myers Squibb (89/100) |
Moz Domain Authority 46/100 vs category average 41 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #656,728 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
Adaptimmune has a dedicated Wikipedia entity - a top-weighted signal AI models rely on to identify and describe the brand.
The homepage meta description reads "Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for cancer patients" (Meta description: 18 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: No robots.txt found (default: all bots allowed, but explicit file preferred) - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Apache.
Social footprint: verified profiles on LinkedIn, X (Twitter), YouTube, Facebook, Instagram, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked September 2026.
When asked "What is Adaptimmune?", Claude could identify the brand as of September 2026. Adaptimmune is a UK-based biopharmaceutical company specializing in T-cell receptor (TCR) engineered cell therapies for treating solid tumor cancers. Its lead product, afami-cel (branded Tecelra), received FDA approval as a treatment for synovial sarcoma, marking a milestone as o Best known for Developing TCR-engineered T-cell therapies for solid tumors, including the FDA-approved afami-cel (Tecelra) for synovial sarcoma.
When asked "Best brands similar to Adaptimmune?", Claude would recommend Adaptimmune as of September 2026. It's a notable name in the cell therapy and oncology space, especially given its regulatory milestone with a solid tumor cell therapy, so I'd mention it if discussing innovative cancer treatment companies.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Adaptimmune's main competitors in Healthcare: Immunocore (75/100), Kite Pharma (Gilead) (83/100), Novartis (71/100), Bristol Myers Squibb (89/100).
Sources: Brand Analyzer scan
Adaptimmune has moderate AI-search visibility, scoring 51/100 on Brand Analyzer's AI visibility composite (visibility 66, trust 29, recommendation 49). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Adaptimmune official site
Adaptimmune was founded in 2008. Adaptimmune operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Adaptimmune is headquartered in Abingdon-on-Thames. Adaptimmune operates in the Healthcare category.
Sources: Wikidata
Adaptimmune scores 49/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority; a Wikipedia presence helps.
Sources: Adaptimmune official site
Adaptimmune is a clinical-stage biopharmaceutical company headquartered in Abingdon-on-Thames, United Kingdom, founded in 2008. It focuses on developing novel cancer immunotherapy products for cancer patients.
Sources: Adaptimmune official site
Adaptimmune engineers cell therapies that use advanced T-cell receptor (TCR) technology to arm a patient's own immune cells to recognize and fight cancer. The company develops these novel immunotherapy products specifically for cancer patients, particularly those with limited existing treatment options.
Sources: Adaptimmune official site
Adaptimmune can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Adaptimmune official site
Adaptimmune is known for pioneering T-cell receptor (TCR) technology in cell therapy, engineering personalized cancer immunotherapies aimed at patients who have few other treatment options.
Sources: Adaptimmune official site
Adaptimmune's therapies and research are intended for cancer patients seeking innovative treatment options. The company also engages healthcare providers, biopharmaceutical investors, and industry partners interested in advancements in cell therapy.
Sources: Adaptimmune official site
Adaptimmune scores 51/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Adaptimmune has a limited AI-visibility profile at 51/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is visibility (66/100) and its weakest is trust (29/100). It benefits from a recognised Wikipedia company entity, a Wikidata knowledge-graph entry and a global traffic rank of #656,728 (Tranco). The main gaps holding it back: thin schema.org structured data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Adaptimmune from memory (September 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Adaptimmune: ACON Labs (80/100), ACCO (American Childhood Cancer Organization) (80/100), Adaptive Biotechnologies (80/100), Addison Group (80/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.